INFECTION OF intravascular catheters remains an important source of morbidity and mortality for critically ill patients.
1-5 New technology for the diagnosis and prevention of catheter-related bloodstream infection (CRBSI) is rapidly evolving.
6 Antimicrobial-coated catheters, ionic silver cuffs, antibiotic-impregnated hubs, and intraluminal antibiotic locks have all been shown
6-10 to reduce the incidence of CRBSI in critically ill patients. However, these prevention strategies are expensive and might increase hospital costs. In the current health care economic climate, the clinical and economic benefit of this new technology must outweigh the increased costs. Population-specific attributable cost estimates for CRBSI will aid in the formal cost-effective analysis of new technology as it becomes available.